Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody
Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody
复制标题
DOI：
10.1002/biof.9
复制
发表时间：
2009-01-01
期刊：
影响因子：
6
通讯作者：
Kishimoto, Tadamitsu
中科院分区：
文献类型：
--
作者：
Mihara, Masahiko;Ohsugi, Yoshiyuki;Kishimoto, Tadamitsu
在几种慢性炎症性自身免疫性疾病中，包括类风湿性关节炎(RA)和炎症性肠病，都发现了白介素6(IL-6)的释放。人源化抗人IL-6受体(IL-6R)抗体tocilizumab的治疗显著改善了RA患者的疾病活动性，并抑制了关节破坏的进展，但IL-6阻断导致RA改善的原因尚不清楚。在本文中，我们讨论了抗IL-6R抗体治疗对Th-17细胞分化的影响，抗IL-6R抗体对自身免疫性疾病动物模型中Th-17细胞分化的影响，以及抗IL-6R抗体在胶原性关节炎小鼠模型中对Th-17细胞的诱导作用的新结果，并得出结论：抗IL-6R抗体抑制小鼠模型中Th-17细胞的分化。这种抑制作用可能与抗IL-6R抗体对自身免疫性疾病的治疗作用有关。(C)2009年国际生物化学和分子生物学联合会，第35卷，第1期，2009年1月/2月，第47-51页。电子邮件：miharamsh@chugai-Pharm.co.jp
Deregulated production of interleukin-6 (IL-6) has been found in several chronic inflammatory autoimmune disorders, including rheumatoid arthritis (RA) and inflammatory bowel diseases. Treatment with tocilizumab, a humanized antihuman IL-6 receptor (IL-6R) antibody, significantly proved disease activity and inhibited the progression of joint destruction in RA patients, but the reason why IL-6 blockade causes improvement of RA is still unclear. In this review, we discuss the influence of anti-IL-6R antibody treatment on the differentiation of Th-17 cells, which are thought to be involved in the pathogenesis of autoimmune diseases in animal models, present new results for the effect of anti-IL-6R antibody on the induction of Th-17 cells in a mouse collagen-induced arthritis model, and come to the conclusion that anti-IL-6R antibody inhibited the differentiation of Th-17 cells in mouse models. It is thought that this inhibitory action may contribute to the therapeutic effects of anti-IL-6R antibody in human autoimmune diseases. (C) 2009 international Union of Biochemistry and Molecular Biology, Inc. Volume 35, Number 1, January/February 2009, Pages 47-51. E-mail: miharamsh@chugai-pharm.co.jp